News Conference News ACC 2024 Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI Michael O'Riordan April 07, 2024
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News ACC 2023 No Downside to Immediate Complete Revascularization in ACS: BIOVASC Michael O'Riordan March 06, 2023
Presentation ACC 2023 Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease Presenter: Roberto Diletti March 05, 2023
News Conference News ACC 2022 No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3 Michael O'Riordan April 13, 2022
News Conference News ACC 2022 FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses Michael O'Riordan April 06, 2022
News Conference News ACC 2022 In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD Caitlin E. Cox April 02, 2022
News Conference News ACC 2020 More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA Michael O'Riordan March 28, 2020
News Conference News ACC 2018 PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats Yael L. Maxwell March 14, 2018
News Conference News ACC 2015 MATRIX Provides Support for Radial Access, Mixed Results for Bivalirudin Todd Neale March 17, 2015
News Conference News ACC 2013 STREAM: Fibrinolysis Strategy Effective for STEMI Patients Far From PCI Hospital Yael L. Maxwell March 09, 2013